Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema
- Registration Number
- NCT05699759
- Lead Sponsor
- Michelle Abou-Jaoude
- Brief Summary
This study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1
- 18 years or older
- BCVA of ≥ 24 and ≤ 73 letters (20/40 or worse but at least 20/320) by an ETDRS chart. BCVA of the non-study eye must be no worse than 20/400)
- Diagnosis of diabetes mellitus, type 1 or 2 with non-proliferative or non-high risk proliferative diabetic retinopathy.
- DME based on investigator's clinical evaluation and demonstrated on fundus photographs, fluorescein angiograms, and spectral domain-optical coherence tomography (SD-OCT)
- Mean foveal thickness of at least 300 µm by SD-OCT
- Ability and willingness to comply with the treatment and follow-up procedures
- Ability to understand and sign the informed consent form
- Intraocular pressure of ≤ 21 on 2 or less IOP lowering medications
- Pregnant patients, currently lactating patients, or females of childbearing potential (unless using reliable contraception such as double barrier, surgical sterilization, oral contraceptives, intrauterine device (IUD), etc.)
- Allergy or hypersensitivity (known or suspected) to fluorescein or any component of the investigational product or delivery system
- Any ocular surgery in the study eye within 12 weeks of screening
- Any history of vitrectomy in the study eye
- Aphakia in the study eye
- Presence of severe foveal ischemia, defined as foveal avascular zone (FAZ) of >1.5 mm2 on OCT-Angiography
- Prior intraocular or periocular treatment for DME
- Macular laser for the treatment of diabetic macular edema within 12 weeks of screening
- Any change in systemic steroidal therapy within 3 months of screening
- Retinal or choroidal neovascularization due to ocular conditions other than diabetic retinopathy
- History or presence of viral disease of the cornea or conjunctiva
- History or presence of any disease or condition that in the investigator's opinion would preclude study treatment or follow-up or that in the opinion of the investigator would render them as unlikely to benefit from study treatment.
- Any lens or corneal opacity which impairs visualization of the posterior pole
- Participation in another clinical trial within 12 weeks before the screening visit or during the study
- Expectation that subject will be moving away from the area of the clinical treatment center without the ability to return for visits within the study period
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Patients with Diabetic Macular Edema K8 Patients with Diabetic Macular Edema
- Primary Outcome Measures
Name Time Method Mean change in central subfield thickness At week 4 (change as measured from baseline) Central subfield thickness (CST) measured on spectral domain-optical coherence tomography (SD-OCT)
Mean change in best-corrected visual acuity (BCVA) At week 4 (change as measured from baseline) best-corrected visual acuity as defined by the number of letters read on the scale set by the ETDRS (Early Treatment of Diabetic Retinopathy Study). (More letters read equates to better visual acuity)
Adverse Events Within the study period (of 24 weeks) Frequency of participants experiencing ocular or systemic adverse events.
- Secondary Outcome Measures
Name Time Method Change in score on the ETDRS Multi-Step Scale of Diabetic Retinopathy 24 weeks The Early Treatment Diabetic Retinopathy Study (ETDRS DRSS) was developed to categorize the severity of diabetic retinopathy based on several fundus photographic characteristics. There are 13 levels in the original ETDRS scale, and a severity step or level increase is associated with an increased risk of retinopathy progression. The scale goes from 10 to 85, with higher scores being worse.
Visual acuity 24 weeks (at 2, 4, 8, 12, 16, and 24 weeks) The proportion of subjects who have an change from baseline of ETDRS letters read of ≥ 5 letters, ≥ 10 letters or ≥ 15 letters of visual acuity.
Resolution of macular edema 24 weeks (at 2, 4, 8, 12, 16, and 24 weeks) Frequency of participants experiencing resolution of macular edema
Clinically significant change in visual acuity 24 weeks (at 2, 4, 8, 12, 16, and 24 weeks) Frequency of participants experiencing clinically significant change.
Change in retinal thickening 24 weeks (at 2, 4, 8, 12, 16, and 24 weeks) Total area in disc diameters of retinal thickening of the lesion involving the foveal center, based on fundus imaging.
Change in hard exudates 24 weeks (at 2, 4, 8, 12, 16, and 24 weeks) Total area in disc diameters of hard exudates in the lesion involving the macula, based on fundus imaging.
Change in foveal avascular zone. 24 weeks (at 2, 4, 8, 12, 16, and 24 weeks) Foveal avascular zone size as determined using OCT-Angiography
Proportion of subjects requiring rescue treatment 24 weeks (at 2, 4, 8, 12, 16, and 24 weeks) Proportion of subjects requiring rescue treatment
Mean change in best-corrected visual acuity (BCVA) at other study timepoints 24 weeks (at 2, 4, 8, 12, 16, and 24 weeks) best-corrected visual acuity as defined by the number of letters read on the scale set by the ETDRS (Early Treatment of Diabetic Retinopathy Study). (More letters read equates to better visual acuity)
Proportion of subjects requiring vitrectomy 24 weeks (at 2, 4, 8, 12, 16, and 24 weeks) Proportion of subjects requiring vitrectomy
Mean change in central subfield thickness at other study timepoints 24 weeks (at 2, 8, 12, 16, and 24 weeks) Central subfield thickness (CST) measured on spectral domain-optical coherence tomography (SD-OCT)
Trial Locations
- Locations (1)
University of Kentucky
🇺🇸Lexington, Kentucky, United States